ABIVAX (ABVX) AGM 2025 summary

Opening remarks and agenda

• The meeting opened with a welcome, remembrance of a key supporter, and a business review, with financial results, strategic orientations, ongoing R&D projects, and future vision on the agenda.

• The assembly was declared regularly constituted with all legal documents available for consultation.

Board and executive committee updates

• Sylvie Grégoire was appointed Board Chair in July 2024, with Dominik Höchli joining the Board in April 2025 and Mark Stenhouse as Board Observer in November 2024.

• Nadège Briancon-Eris joined the executive committee, focusing on strategy.

• Leadership team brings extensive experience in drug development and commercialization.

Financial performance review

• Operating income rose to €12.4M in 2024, a 169% increase from 2023.

• Operating expenses increased by 40% to €185.4M, mainly due to higher R&D and administrative costs.

• Net loss widened to €176.2M in 2024, up 19% from the previous year.

• Cash at end-2024 was €103.6M, with funding expected to last into Q4 2025; additional financing options are being explored.

• Share price declined 34.1% in 2024 but rebounded with a 10.2% YTD gain in 2025 amid positive trial momentum.